Operating Lease Liabilities (Current)
Alnylam Pharmaceuticals Operating Lease Liabilities (Current) increased by 0.3% to $45.66M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.8%, from $46.01M to $45.66M. Over 5 years (FY 2020 to FY 2025), Operating Lease Liabilities (Current) shows an upward trend with a 4.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase suggests an expanding physical footprint or upcoming renewals, while a decrease may indicate store closures or a shift toward asset ownership.
Detailed definition
The portion of operating lease payments due within the next twelve months, representing the short-term obligation for re...
Peer comparison
Retail-heavy tech companies often show higher current lease liabilities compared to pure software firms due to physical storefront presence.
operating_lease_liabilities_currentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $39.36M | $40.61M | $40.55M | $41.29M | $41.24M | $41.58M | $41.97M | $43.06M | $42.07M | $41.52M | $41.51M | $41.67M | $41.66M | $42.14M | $41.89M | $46.01M | $46.10M | $44.76M | $45.52M | $45.66M |
| QoQ Change | — | +3.2% | -0.2% | +1.8% | -0.1% | +0.8% | +0.9% | +2.6% | -2.3% | -1.3% | -0.0% | +0.4% | -0.0% | +1.2% | -0.6% | +9.8% | +0.2% | -2.9% | +1.7% | +0.3% |
| YoY Change | — | — | — | — | +4.8% | +2.4% | +3.5% | +4.3% | +2.0% | -0.2% | -1.1% | -3.2% | -1.0% | +1.5% | +0.9% | +10.4% | +10.7% | +6.2% | +8.7% | -0.8% |
Operating Lease Liabilities (Current) at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's operating lease liabilities (current)?
- Alnylam Pharmaceuticals (ALNY) reported operating lease liabilities (current) of $45.66M in Q1 2026.
- How has Alnylam Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Alnylam Pharmaceuticals's operating lease liabilities (current) decreased by 0.8% year-over-year, from $46.01M to $45.66M.
- What is the long-term trend for Alnylam Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's operating lease liabilities (current) has grown at a 4.3% compound annual growth rate (CAGR), from $36.87M to $45.52M.
- What does operating lease liabilities (current) mean?
- The amount of rent and lease payments the company must pay in the next year.